Titan Biotech Limited (BOM:524717)
India · Delayed Price · Currency is INR 366.40
+16.80 (4.81%)
At close: Nov 9, 2026
Titan Biotech Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 6, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 18,924 | 18,911 | 3,484 | 4,365 | 1,627 | 2,166 | |
Market Cap Growth | 135.49% | 442.88% | -20.19% | 168.33% | -24.88% | 41.23% |
Enterprise Value | 18,936 | 18,964 | 3,409 | 4,405 | 1,665 | 2,381 |
Last Close Price | 366.40 | 365.71 | 67.22 | 83.97 | 31.13 | 41.22 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 6, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 44.08 | 63.28 | 16.18 | 17.56 | 6.55 | 9.99 |
PS Ratio | 7.85 | 9.17 | 2.23 | 2.66 | 1.13 | 1.75 |
PB Ratio | 9.33 | 10.42 | 2.27 | 3.27 | 1.48 | 2.51 |
P/TBV Ratio | 9.33 | 10.42 | 2.27 | 3.27 | 1.48 | 2.51 |
P/FCF Ratio | 90.50 | 82.25 | 30.02 | 262.72 | 19.26 | 13.77 |
P/OCF Ratio | 58.68 | 62.17 | 17.31 | 20.64 | 7.68 | 9.82 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 6, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 7.86 | 9.20 | 2.18 | 2.69 | 1.16 | 1.93 |
EV/EBITDA Ratio | 36.90 | 50.07 | 13.75 | 13.09 | 5.76 | 7.74 |
EV/EBIT Ratio | 41.09 | 56.56 | 16.15 | 14.30 | 6.21 | 8.26 |
EV/FCF Ratio | 90.56 | 82.48 | 29.38 | 265.13 | 19.72 | 15.14 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 6, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.03 | 0.03 | 0.02 | 0.07 | 0.08 | 0.10 |
Debt / EBITDA Ratio | 0.12 | 0.16 | 0.13 | 0.26 | 0.29 | 0.29 |
Debt / FCF Ratio | 0.28 | 0.27 | 0.28 | 5.27 | 1.01 | 0.57 |
Net Debt / Equity Ratio | 0.01 | 0.02 | -0.01 | 0.04 | 0.03 | 0.03 |
Net Debt / EBITDA Ratio | 0.03 | 0.11 | -0.09 | 0.16 | 0.13 | 0.07 |
Net Debt / FCF Ratio | 0.06 | 0.18 | -0.20 | 3.29 | 0.43 | 0.13 |
Asset Turnover | 1.08 | 1.06 | 0.94 | 1.13 | 1.19 | 1.18 |
Inventory Turnover | 2.13 | 1.85 | 1.54 | 1.88 | 2.01 | 1.78 |
Quick Ratio | 0.89 | 0.95 | 1.37 | 1.12 | 1.27 | 1.37 |
Current Ratio | 3.05 | 3.28 | 4.48 | 3.71 | 3.36 | 3.76 |
Return on Equity (ROE) | 20.94% | 17.84% | 15.01% | 20.42% | 25.33% | 27.32% |
Return on Assets (ROA) | 11.89% | 10.79% | 7.95% | 13.21% | 13.81% | 17.25% |
Return on Invested Capital (ROIC) | 16.23% | 14.65% | 11.35% | 18.54% | 20.66% | 25.17% |
Return on Capital Employed (ROCE) | 20.30% | 17.80% | 13.40% | 22.40% | 23.50% | 31.60% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 6, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 2.27% | 1.58% | 6.18% | 5.69% | 15.27% | 10.01% |
FCF Yield | 1.10% | 1.22% | 3.33% | 0.38% | 5.19% | 7.26% |
Dividend Yield | 0.11% | 0.11% | 0.47% | 0.38% | 0.91% | 0.57% |
Payout Ratio | 5.34% | 5.53% | 7.68% | 5.99% | 4.99% | 5.72% |
Total Shareholder Return | 10.09% | 0.11% | 0.47% | 0.38% | 0.91% | 0.57% |